220 related articles for article (PubMed ID: 36552834)
1. eIF4A/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative Breast Cancer Cell Model.
González-Ortiz A; Pulido-Capiz A; Castañeda-Sánchez CY; Ibarra-López E; Galindo-Hernández O; Calderón-Fernández MA; López-Cossio LY; Díaz-Molina R; Chimal-Vega B; Serafín-Higuera N; Córdova-Guerrero I; García-González V
Cells; 2022 Dec; 11(24):. PubMed ID: 36552834
[TBL] [Abstract][Full Text] [Related]
2. Low-Density Lipoproteins Increase Proliferation, Invasion, and Chemoresistance via an Exosome Autocrine Mechanism in MDA-MB-231 Chemoresistant Cells.
Castañeda-Sánchez CY; Chimal-Vega B; León-Gutiérrez R; Araiza-Robles AE; Serafín-Higuera N; Pulido-Capiz A; Rivero IA; Díaz-Molina R; Alatorre-Meda M; Rodríguez-Velázquez E; García-González V
Biomedicines; 2024 Mar; 12(4):. PubMed ID: 38672098
[TBL] [Abstract][Full Text] [Related]
3. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation.
Yang HS; Jansen AP; Komar AA; Zheng X; Merrick WC; Costes S; Lockett SJ; Sonenberg N; Colburn NH
Mol Cell Biol; 2003 Jan; 23(1):26-37. PubMed ID: 12482958
[TBL] [Abstract][Full Text] [Related]
4. Programmed cell death 4 mechanism of action: The model to be updated?
Vikhreva PN; Kalinichenko SV; Korobko IV
Cell Cycle; 2017 Oct; 16(19):1761-1764. PubMed ID: 28853972
[TBL] [Abstract][Full Text] [Related]
5. A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A.
Yang HS; Cho MH; Zakowicz H; Hegamyer G; Sonenberg N; Colburn NH
Mol Cell Biol; 2004 May; 24(9):3894-906. PubMed ID: 15082783
[TBL] [Abstract][Full Text] [Related]
6. PDCD4 inhibits translation initiation by binding to eIF4A using both its MA3 domains.
Suzuki C; Garces RG; Edmonds KA; Hiller S; Hyberts SG; Marintchev A; Wagner G
Proc Natl Acad Sci U S A; 2008 Mar; 105(9):3274-9. PubMed ID: 18296639
[TBL] [Abstract][Full Text] [Related]
7. RSK-mediated down-regulation of PDCD4 is required for proliferation, survival, and migration in a model of triple-negative breast cancer.
Cuesta R; Holz MK
Oncotarget; 2016 May; 7(19):27567-83. PubMed ID: 27028868
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor Pdcd4 and eIF4GI.
Zakowicz H; Yang HS; Stark C; Wlodawer A; Laronde-Leblanc N; Colburn NH
RNA; 2005 Mar; 11(3):261-74. PubMed ID: 15661843
[TBL] [Abstract][Full Text] [Related]
9. Structure of the tandem MA-3 region of Pdcd4 protein and characterization of its interactions with eIF4A and eIF4G: molecular mechanisms of a tumor suppressor.
Waters LC; Strong SL; Ferlemann E; Oka O; Muskett FW; Veverka V; Banerjee S; Schmedt T; Henry AJ; Klempnauer KH; Carr MD
J Biol Chem; 2011 May; 286(19):17270-80. PubMed ID: 21454508
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor Pdcd4 attenuates Sin1 translation to inhibit invasion in colon carcinoma.
Wang Q; Zhu J; Wang YW; Dai Y; Wang YL; Wang C; Liu J; Baker A; Colburn NH; Yang HS
Oncogene; 2017 Nov; 36(45):6225-6234. PubMed ID: 28692058
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for translational inhibition by the tumour suppressor Pdcd4.
Loh PG; Yang HS; Walsh MA; Wang Q; Wang X; Cheng Z; Liu D; Song H
EMBO J; 2009 Feb; 28(3):274-85. PubMed ID: 19153607
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.
Steinhardt JJ; Peroutka RJ; Mazan-Mamczarz K; Chen Q; Houng S; Robles C; Barth RN; DuBose J; Bruns B; Tesoriero R; Stein D; Fang R; Hanna N; Pasley J; Rodriguez C; Kligman MD; Bradley M; Rabin J; Shackelford S; Dai B; Landon AL; Scalea T; Livak F; Gartenhaus RB
Blood; 2014 Dec; 124(25):3758-67. PubMed ID: 25320244
[TBL] [Abstract][Full Text] [Related]
13. A novel mechanism for the control of translation of specific mRNAs by tumor suppressor protein Pdcd4: inhibition of translation elongation.
Biyanee A; Ohnheiser J; Singh P; Klempnauer KH
Oncogene; 2015 Mar; 34(11):1384-92. PubMed ID: 24681950
[TBL] [Abstract][Full Text] [Related]
14. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
[TBL] [Abstract][Full Text] [Related]
15. Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein.
Jin C; Rajabi H; Rodrigo CM; Porco JA; Kufe D
Oncogene; 2013 Apr; 32(17):2179-88. PubMed ID: 22689062
[TBL] [Abstract][Full Text] [Related]
16. Structure of the C-terminal MA-3 domain of the tumour suppressor protein Pdcd4 and characterization of its interaction with eIF4A.
Waters LC; Veverka V; Böhm M; Schmedt T; Choong PT; Muskett FW; Klempnauer KH; Carr MD
Oncogene; 2007 Jul; 26(34):4941-50. PubMed ID: 17310995
[TBL] [Abstract][Full Text] [Related]
17. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
18. Targeting of the Eukaryotic Translation Initiation Factor 4A Against Breast Cancer Stemness.
Sridharan S; Robeson M; Bastihalli-Tukaramrao D; Howard CM; Subramaniyan B; Tilley AMC; Tiwari AK; Raman D
Front Oncol; 2019; 9():1311. PubMed ID: 31867270
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of the eIF4A-PDCD4 complex.
Chang JH; Cho YH; Sohn SY; Choi JM; Kim A; Kim YC; Jang SK; Cho Y
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3148-53. PubMed ID: 19204291
[TBL] [Abstract][Full Text] [Related]
20. M
Liu X; Li P; Huang Y; Li H; Liu X; Du Y; Lin X; Chen D; Liu H; Zhou Y
Redox Biol; 2024 Feb; 69():102993. PubMed ID: 38104484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
